Amferia closes €1,2 million investment to combat resistant bacterial infections
Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its mission to combat wound infections. During 2024, Amferia has signed important commercial agreements with leading animal health companies in Europe for commercialization of the company’s proprietary technology — a wound dressing for animals that also kills resistant bacteria.Mölndal, Sweden (September 3rd, 2024): Amferia, a Swedish medtech company focused on developing innovative antimicrobial healthcare solutions, announces the successful closure of a 1.2-million-euro investment